Establishment Labs (NASDAQ:ESTA) Price Target Raised to $72.00

Establishment Labs (NASDAQ:ESTA) had its price objective raised by equities researchers at Canaccord Genuity Group from $60.00 to $72.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 10.95% from the stock’s previous close.

ESTA has been the subject of a number of other reports. Mizuho upped their price target on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Tuesday, October 7th. BTIG Research lifted their target price on Establishment Labs from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen upgraded Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Establishment Labs Stock Performance

Shares of Establishment Labs stock traded up $4.39 during trading hours on Thursday, reaching $64.90. 1,071,251 shares of the stock traded hands, compared to its average volume of 490,987. The company has a 50 day moving average price of $43.18 and a 200 day moving average price of $39.99. Establishment Labs has a one year low of $26.56 and a one year high of $65.10. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -21.24 and a beta of 0.98.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $53.78 million during the quarter, compared to analysts’ expectations of $52.28 million. During the same period in the prior year, the company earned ($0.59) earnings per share. The firm’s revenue was up 33.8% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new position in Establishment Labs in the third quarter worth about $71,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Establishment Labs in the 1st quarter worth approximately $81,000. Osaic Holdings Inc. grew its position in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. CWM LLC raised its stake in shares of Establishment Labs by 45.9% during the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after acquiring an additional 686 shares in the last quarter. Finally, Brian Low Financial Group LLC purchased a new stake in Establishment Labs during the third quarter valued at approximately $223,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.